Could this be the secret to Pfizer's rebound strategy?

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk ...

A recent study pinpoints the two leading GLP-1 manufacturers as the top pharma companies cited the most across leading AI ...

Can a pharmaceutical company build "power brands" the way consumer giants do? In this exclusive Fortune India: In ...

A 7% dividend yield will grab your attention, but be sure to read the fine print.

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow.

In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T Biologics' ...

The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

New York City’s buildings commissioner said late Tuesday that the building was stable for now, hours after officials set up a ...

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...

Pfizer stock has been the worst performer among its large-cap U.S. peers over the past 10 years ...